Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial.

ABSTRACT:

Objective

The aim of these analyses was to investigate the rate of decline in forced vital capacity (FVC) in patients with SSc-associated interstitial lung disease (SSc-ILD) with and without cough or dyspnoea in the SENSCIS trial.

Methods

Patients in the SENSCIS trial were randomized to receive nintedanib or placebo. Subgroups with and without cough or dyspnoea at baseline were defined by responses to the St George's Respiratory Questionnaire.

Results

At baseline, 114/575 patients (19.8%) did not have cough and 172/574 patients (30.0%) did not have dyspnoea. In the placebo group, the rate of FVC decline over 52 weeks was similar in patients with and without cough (-95.6 and -83.4 mL/year, respectively) or dyspnoea (-95.8 and -87.7 mL/year, respectively). The effect of

SUBMITTER: Volkmann ER 

PROVIDER: S-EPMC9629379 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature